The totality of evidence from large-scale, randomized, controlled clinical trials and mechanistic studies in the laboratory has provided six crucial lessons about the emerging role of SGLT2 inhibitors to prevent the onset of heart failure in patients at high risk and slow the progression of heart failure in patients with established disease.

Wearable devices are widely used and have a high level of societal acceptance, opening unimagined and unexploited possibilities in cardiovascular medicine. In this Clinical Outlook, we highlight the disruptive potential of wearables for cardiovascular disease prevention, diagnosis and management, and suggest strategies for quickly and safely translating these lifestyle products into medical devices.

Transcatheter aortic valve implantation (TAVI) is a breakthrough technology to replace the aortic valve in patients with severe aortic stenosis using simple cardiac catheterization instead of thoracic surgery. Initiated 20 years ago by my colleagues and me, TAVI has been performed in >1.5 million patients globally and has profoundly altered the landscape of cardiovascular medicine.

Different Notch ligands have opposing roles in regulating the proliferation and differentiation of vascular smooth muscle cells in the pulmonary vasculature in pulmonary arterial hypertension. Selectively targeting Jagged 1–NOTCH3 signalling might be an effective and safe strategy for the treatment of this condition.